trending Market Intelligence /marketintelligence/en/news-insights/trending/5u_2nzbzAvo611ITF4LI-A2 content esgSubNav
In This List

Paris court rules against Onxeo in SpePharm, SpeBio dispute

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Paris court rules against Onxeo in SpePharm, SpeBio dispute

The Commercial Court of Paris ruled against Onxeo SA in its dispute with SpePharm and their 50-50 joint venture SpeBio BV.

SpeBio BV was formed to distribute Loramyc for the treatment of oropharyngeal candidiasis, a yeast/fungal infection.

The court directed Onxeo to pay SpePharm and SpeBio €50,000 and €8.6 million in damages, respectively. SpePharm and SpeBio will also receive procedural indemnities of €15,000 and €250,000, respectively.

Onxeo said it will contest the decision.

The dispute, which Onxeo started in 2009, involves alleged contract breaches by SpePharm and SpeBio that resulted in a delay in the marketing and sales of Loramyc.

Onxeo was formerly known as BioAlliance Pharma.